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ABSTRACT
Methods: The data collected for reviewing was by studying the published researchers from PubMed, Web of Science, Medline, Science Direct, Excerpta 
Medica Database, Cochrane, Elton B. Stephens Company (EBSCO), and Google open access publications from the year 1995–2017.
Results: We have concluded on an interpretation that the drugs for treating DNP are managing the pain and controlling glucose levels but are 
reportedly causing major side effects. Hence, attention must be given to the potential risk factors for neuropathy and development of formulations 
with minimal side effects and a potential cure. We have focused on the recent researches, emerging problems, and techniques for identifying the 
patients suffering from DNP.
Conclusion: The incidence of DNP is a prominent complication for people suffering from diabetes. Although the treatment available currently focusses 
on the pain management in DNP, attention must be given to the potential risk factors for neuropathy and development of formulations with minimal 
side effects and a potential cure.
Keywords: Diabetic neuropathy, Diabetes mellitus, Distal symmetric polyneuropathy, Chronic complications, Antidepressant, Ethnomedicine, 
Pathways of diabetic neuropathy.
INTRODUCTION
Diabetes mellitus (DM)
Diabetes is a common disease associated with neurological 
complications which are a pressing problem for the patient throughout 
the world [1]. A study revealed that at least half of the people who have 
Type 1 diabetes develop some form of neuropathy in their lifespan [2]. 
This is the most common complication of DM, wherein type 1 diabetes 
the distal polyneuropathy is symptomatic even after many years of 
diagnosis, while the Type 2 patients may be suffering from neuropathy 
at the time of diagnosis [3].
DM is a disorder, in which the elevated blood glucose levels are exhibited 
due to absence (partial or total) of insulin levels in the body. It is a huge 
problem among people aged 45–64 years, and people are more likely 
to suffer from complications of diabetes such as diabetic retinopathy, 
diabetic neuropathy (DNP), thirst, itchy skin, delay in wound healing, 
and multiple other clinical complications [3,4]. DM is a prolonged 
disease which has been prevalent, and it is increasing all around the 
world. The pattern is predicted to double in the coming years as the 
countries are heading to have more aged people than now.
The major problem faced in case of diabetes is that the people who are 
suffering from it are still unknown about the disease. DM is common 
in people who have physical inactivity, obesity, and weight issues [5].
According to the World Health Organization, the world has a total 
population of about 350 million diabetics which is supposed to increase 
by 50% until the year 2030. It has also been proposed that diabetes 
would be one of the 7th leading causes of death among the people [6].
This review will give an insight into the complications of diabetes which 
is DNP. The novelty of the paper is to showcase the types, symptoms, 
mechanisms, available treatment, and side effects of treatment for DNP.
Types of DM
Based on the classification, there are three types of DM commonly 
two types of diabetes are known to people who are type 1 DM and 
type 2 DM. The third uncommon one is gestational diabetes  [7]. In all 
the categories, hyperglycemia is a common characteristic. The type 1 
diabetes is a result of the partial or total lack of insulin production. The 
type 2 diabetes is a consequence of insulin resistance, impaired insulin 
secretions, and heightened glucose production in various cases [8].
The third type which is gestational diabetes is common in pregnant women 
who have a change of developing diabetes during their pregnancies. 
Although the situation goes back to normal after the pregnancy is over, 
the chances of them developing diabetes later in life are more likely than 
the rest. Approximately 4% of pregnant women in the United States 
tend to acquire gestational diabetes [8]. A research study conducted in 
India by Zagar et al. stated that approximately 3.8% gestational DM is 
dominant and with the increased age of patient the chances of diabetes 
are substantial [9]. As per the National Health and Medical Research 
Council (2005) guidelines, for the management of Type 2 DM, the glucose 
levels for non-diabetics and diabetics are as mentioned in Table 1 [9,10].
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Objective: The incidence of diabetic neuropathy (DNP) is a prominent complication for people suffering from diabetes. DNP is 
a common complication in patients suffering from diabetes, and it is affecting approximately more than 50% of the population where the nerves 
are affected by high glucose levels.
The aim of the review paper is to inspect the complications, causes, diagnosis, pathogenesis, treatments, pathways, and management of DNP 
as all these factors play important role in the management of DNP. This paper also aims to identify the potential cures and the side effects if any 
associated with the commonly used treatments in conditions of DNP.
Complications of diabetes
Depending on the severity of the disease, diabetes can be classified as 
following types:
• Acute complications (or diabetic emergencies)
 The acute complications of diabetes are diabetic ketoacidosis and 
hypoglycemia
• Chronic complications
The problems arising in chronic diabetes are classified as either
 a. Microvascular complications or
 b. Macrovascular complications.
The problems associated with microvascular complications are 
diabetic retinopathy [11-13]. Diabetic nephropathy and diabetic skin 
problems (the “diabetic foot”) are also among the major microvascular 
complications of diabetes. Whereas the macrovascular complications 
can cause problems such as arteriosclerosis, peripheral vascular 
disease/coronary heart disease, hypertension, myocardial infarction, 
and cerebrovascular disease [14,15].
DNP
DNP is a disease or a clinical condition where the peripheral nerves are 
damaged as a result of DM. This causes a major effect on the autonomic 
as well as the somatic nervous system [16]. It has been reported that 
diabetic peripheral neuropathy is very painful and this condition can 
only be relieved by medication. The various classifications of diabetic 
neuropathies are mentioned in Table 2 [17].
Nearly 8% of the newly diagnosed patients have found to shown diabetic 
neuropathic conditions, whereas 50% patients with long-standing 
disease showed the symptoms of DNP [18,19]. It has been observed 
and reported that the DNP is more severe and painful at night [20,21].
Our review paper focuses on the collection of authentic information 
about DNP, the plants extract which are potential cures for the DNP are 
being used traditionally by people under ayurveda for the treatment of 
diabetes which have proved to be very useful till date therefore more 
research is required in the development of an ayurvedic preparation 
from herbal extracts as a standard treatment for curing diabetes and 
diabetic neuropathy. 
Underneath we have discussed the synthetically prepared medical 
formulations and different classifications of drugs being used currently 
in the treatment of Diabetic Neuropathy and most importantly in 
controlling the inflammation and pain. As a painful neuropathy 
condition is a common and discomforting problem with prolonged DM. 
Therefore, commonly used tricyclic antidepressant drugs and other 
analgesics have been used to get relief from the painful neuropathic 
pain in some patients, but there is no agent who is completely giving 
relief from the pain, and high doses of the medications are reportedly 
causing adverse reactions [15]. The complications of diabetes cause 
diabetic neuropathies, whereas the neuropathic condition can arise by 
multiple factors shown in Fig. 1.
Diabetic symmetric distal polyneuropathy (DSDP)
The DSDP associated with autonomic neuropathy is a commonly 
observed DNP where the distal distribution of sensory and motor 
symptoms and signs along the length. The autonomic association with 
DSDP is a crucial part of the clinical complexes thus both of them are 
noted and considered together [22].
Search engine
A thorough review of published articles on PubMed, Web of Science, 
Medline, Science Direct, Excerpta Medica Database (EMBASE), 
Cochrane, EBSCO, and Google open access by searching keywords 
such as “DNP, DM, Medications for DNP” was performed. In addition, 
articles were also obtained from online sites, newspapers, peer review, 
magazines, and Google Scholar. The review contained information from 
published sources on diabetes, DNP, and its treatment.
Data abstraction and analysis
We have attempted to review the published researches on DNP, its 
pathways, treatment, and the side effects observed. This paper also 
focuses on the research conducted from 1995 to 2017 on patients 
suffering from DNP. The medications given as a treatment for treating 
DNP has shown side effects.
Causes
Major causes of neuropathy
DNP is a nervous disorder which is majorly seen in people suffering 
from diabetes. Whereas, when we categorize them, there are different 
types and causes of DNP. Numerous researches these days are directed 
to study the nerve damage caused by continuous high levels of glucose 
in blood in case of a diabetic patient.






Diabetes implausible Below 5.5 Below 5.5
Diabetes ambiguous 
(must be rechecked by 
a medical practitioner)
5.5–6.9 5.5–11
Diabetes possible 7 or above 11.1 or above
Diabetics
Low (“hypoglycemia”) Below 4 Below 4
Normal 4–6 4–7.7
Moderate 6.1–6.9 7.8–10.9
High (“hyperglycemia”) Above 7 Above 11
Table 2: Classification of diabetic neuropathies‑based on 
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Fig. 1: Probable causes of different types of neuropathy
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Multiple factors or combination of factors altogether can also cause 
nerve damage which is as follows and illustrated by Table 3 and Fig. 1:
• Abnormal fat levels in the body, prolonged duration of diabetes, and 
metabolic factors with potentially low levels of insulin
• A severe mechanical injury to nerves as in case of carpal tunnel 
syndrome
• Certain autoimmune factors or disorders which cause nerve 
inflammation
• Possible inherited traits which are responsible for increasing the 
susceptibility to nerve diseases
• Multiple neurovascular factors which result in leading damage to 
the blood vessels which are responsible for carrying oxygen and 
nutrients to nerves.
• Habits and lifestyle factors such as smoking, alcohol consumption, 
and drug abuse are also responsible for nerve damage in prolonged 
duration [25,26].
Diagnosis
The medical practitioners and diabetologists must refer the patients 
suffering from neuropathies to more specialized testing by neurologists 
and accessing of complex and detailed parameters to know the extent 
of damage, possible zones affected, prior detection of neuropathies, and 
sensitive/prone areas of damage during chronic diabetes condition. A lot 
of different scoring systems and inflammatory parameters are monitored 
for generating a detailed result of neuropathies. An amalgamation of 
typical symptoms of neuropathy with sensory loss and lack of reflexes 
is a direct indication of DNP. The condition of DNP has to be checked and 
carefully examined annually or biannually for better analysis.
A patient or anyone suspected of diabetes has to get screened for 
DNP by observing methods such as pinprick test, temperature test, 
perception of vibration test using tuning fork (128Hz tuning fork), 
checking ankle reflexes, and examining the distal hallux sensitivity 
using 10g monofilament pressure sensation [28].
Usually, multiple tests are performed which makes the testing 87% 
sensitive in the detection of DNP. A loss of sensation, perception, and 
reduced vibration is observed by the diagnosis test performed using 
a 10 g monofilament which predicts foot ulcers therefore it is very 
popularly being used in the diagnosis of Diabetic Neuropathy (DNP). 
The damage to the nerves and the extent of damage is easily identified 
by using monofilaments and studies have also shown that clinical tests 
performed are a good diagnosis of prospected risk for foot ulcers [29].
Therefore, the feet must also be examined and inspected for any 
deformities, ulcers, calluses.
Physiological examination of DNP
The duration and degree of hyperglycemia is a cause for the severity, 
frequency, and progression of neuropathy. Multiple types of research 
such as diabetes control and complication trials have stated that the 
incidences of neuropathy have improved and stabilized by controlled 
glucose levels [30].
The staging of clinical neurological scales can be used for assessing the 
severity of DNP as mentioned in Table 4 [31].
Other investigating methods for DNP
Imaging is an advantageous tool for the diagnosis and management 
of DNP. Therefore, in clinical setups, the magnetic resonance imaging 
performed for the cervical, thoracic, or lumbar regions could be a great 
help in identifying the symptoms of DNP.
Quantitative sensory testing
It is a test performed to interpret the ability of a person to detect 
sensory stimuli. Such sensory tests are used to identify the zones where 
the sensory losses have occurred majorly. These tests will work the best 
when there is complete cooperation, concentration, and comprehension 
of the patient during testing.
Semmes–Weinstein monofilaments
In this test a set of nylon filaments are called the monofilaments is 
used which clips at a preset force on application to the testing site of 
numbness or nerve damage or the site to be tested for DN (Diabetic 
Neuropathy). These filaments give pretty accurate results and are being 
widely used in clinical practice for identification of diabetic patients 
who are at higher risks of DNP and neuropathic foot ulcerations. The 
prediction of neuropathic ulceration can be showcased if the subject is 
unable to perceive a 10 g monofilament.
Vibrations and perceptions
Vibration perception thresholds (VPTs) are assessed by several devices 
for testing a myelinated fiber function. The VPT increases with the age 
of individuals and they are higher in the lower extremity areas. They are 
used to estimate the risks of ulcerations and neuropathies. An abnormal 
reading of 25 V is linked to high risks.
Computer‑assisted sensory examination
Using a computerized device for observing and analyzing the zones of 
touch, pressure, vibration, temperature changes thresholds is a state of 
art technique used in clinical trials for identifying neuropathic zones (the 
zones which are highly affected by prolonged diabetes and have now 
caused nerve damage, loss of sensation in limbs, tingling feeling etc.). 
This has been used successfully in many therapeutic interventions [18].
Autonomic functionality testing
The autonomic dysfunction of the cardiovascular region can be assessed 
by using Ewing and Clarke’s battery for five tests which are as follows:
• An average of inspiratory and expiratory heart rate difference with 
deep breaths
• The 30:50 ratios
• The Valsalva ratio
• The diastolic blood pressure response to the isometric exercises
• The fall in systolic blood pressure to standing [32].
Mechanisms
Pathological mechanism
The radical increase in diabetic patients creates a major problem in the 
care of neuropathy. Therefore, the need to explore the pathogenesis to 
develop effective treatment was required.
Recent clinical research and studies have shown the characteristics 
of the pathophysiology of DNP. The pathology was found to be a 
progressive nerve fiber loss which gave rise to clinical symptoms 










Table 4: Different staging’s of neuropathy [31]
Staging Signs
NO No sign of neuropathy
N1a Signs reported but no symptoms of neuropathy
N2a Symptomatic but mild diabetic polyneuropathy observed
N2b Severe symptomatic diabetic polyneuropathy 
reported (as in N2a but patient unable to heel walk)
N3 Disabling diabetic polyneuropathy
114
 Saraswat et al. 
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 112-119
such as paresthesia, pain, and loss of sensation. The loss of nerve fiber 
takes the form of a distal gradient. Other symptoms like endoneurial 
microangiopathic changes are an important feature of peripheral nerve 
pathology, and this creates a negative impact on the nerve fiber density.
People experiencing impaired glucose tolerance levels are also 
identified with vascular changes, loss of distal nerve fiber, and pave the 
way the for loss of nerve fibers in the nerve stem of lower limbs. [33,34].
The major multiple pathogenic mechanisms which are the underlying 
causes of nerve damage and nerve fiber losses are polyol pathway, 
reactive oxygen species (ROS), glycation, and altered protein kinase C 
(PKC) activity [33].
The development of DNP pivots around many factors and processes such 
as hyperglomerular filtration, inflammation channels, metabolic pathways, 
and oxidative stress conditions [34]. When the diabetic condition persists 
then the arterioles are dilated, the blood flow and glomeruli are increased 
and an elevation in intraglomerular pressure is noted.
These changes in the physiology induce inflammation as well as oxidative 
stress in the glomeruli, therefore, leading to excessive production 
of extracellular matrix which leads to the gradual development of 
glomerulosclerosis. There is no specific therapy designed to cure DN. 
Therefore, managing hyperglycemia, dyslipidemia, and hypertension is 
the ultimate cure for treating it to date.
DNP: Pathways associated
Over the last 30 years, the research in the field of DNP has been 
concentrated on these pathways involved in the development of DNP. 
The main components included in the study are the redox and metabolic 
state of dorsal root ganglions and Schwann cells. A lot of work has 
been focused on the interpretation of polyol pathways, hexosamine 
pathways, and pathways of isoforms of PKC, accumulation of (advanced 
glycation end products [AGEs]) in the DNP exhibiting nerve as well as 
the excess glucose and fatty acid reflux.
Polyol pathway
The excess amount of glucose is eventually converted by aldose 
reductase into sorbitol which develops an osmotic imbalance in the 
cell. This leads to osmotic stress and efflux of myoinositol and taurine. 
Therefore, myoinositol which is an integral part of sodium/potassium 
ATPase harms the normal physiology of the nerve cell.
Another improper activity is occurring along with the prior abnormality 
which the aldose reductase activity was impending a decrease in 
cellular stores of nicotinamide adenine dinucleotide phosphate which 
is required for generation of NO and regeneration of glutathione (an 
essential antioxidant).
The pathway leads to the formation of ROS which altogether disturbs 
the physiology of cell causing cellular dysfunction and ROS-mediated 
cell injury. The hypothesis is called “metabolic reflux hypothesis.” [35]
A set of preclinical studies performed on streptozotocin (STZ) rat models 
of T1D highlighted the activation of the polyol pathway and outlined the 
impaired peripheral nervous system (PNS) structures and functions [36].
Hexosamine and PKC pathways
An increased pace of glycolysis due to increased glucose also increases 
the metabolic disrupting pathways which are altogether speeding the 
neuronal injury.
Fructose-6-phosphate, the glycolysis intermediate enters the hexosamine 
pathway and has to undergo a chain of reaction leading to the formation 
of uridine 5-diphosphate-N-acetylglucosamine (GlcNac). GlcNac is a 
sugar moiety which has the capacity to bind serine/threonine residues 
on SP-1, promoting lipid dyshomeostasis, inflammation, and injury of 
complication-prone tissues basically including the peripheral nerves [37].
End products of advanced glycation
In case of Maillard reaction, the amino acids react with glucose on 
protein molecules leading to the formation of Amadori products. They 
in a long time produce irreversible glycation products like AGEs.
The crosslink formed between AGEs and essential proteins creating 
cellular damage and altered functioning. Secondarily, AGE shows 
binding with receptor of AGE (RAGE) and potentiates downstream 
signaling cascade which is mediated by activation of nuclear factor NF-
kB, this is poisonous.
A huge loss of neurotrophic support, vasoconstriction, and inflammation 
are recorded in case of a rodent PNS after AGE activated its receptor 
RAGE [38]. Accumulation of AGE has been reported in patients suffering 
from DNP as well as T2D [39].
DNP ‑ treatment
Antidepressants
Tri cyclic antidepressants (TCA’s)
The TCA’s – amitriptyline, nortriptyline, and imipramine function by 
inhibiting reuptake of norepinephrine and serotonin. NICE guidelines 
have recommended the use of amitriptyline as the first-line drug in 
treating the DNP. Nortriptyline/amitriptyline must be given at low 
doses like, e.g., 10 mg at night to an increased dose of 150 mg on 
week 21.
A lot of cholinergic side effects have been reported and patient is opting 
for TCA drug withdrawal. Multiple side effects such as dry mouth, 
blurred vision, sedation arrhythmias, urinary retention, orthostatic 
hypotension, and weight gain. Comparatively, nortriptyline is better 
tolerated due to lesser anticholinergic side effects. There are some 
contraindications of using TCAs: Patients of myocardial infarction, 
cardiac conduction defects, prostatic hypertrophy, and closed-angle 
glaucoma must refrain from using TCAs [40-45].
Serotonin–norepinephrine reuptake inhibitors
According to the NICE guidelines, the first-line drug for the treatment 
of painful DNP is duloxetine. This drug has a balanced action on both 
norepinephrine and serotonin reuptake at the presynaptic junction. 
The drug has equal antidepressant and analgesic properties. The initial 
doses are given as low as 30–60 mg and increased to 120 mg on the 
basis of side effects and tolerance [46-50].
It is always recommended to keep low initial doses in starting of 
treatment followed by a gradual increase in the dose concentration. 
The commonly reported side effects are sweating, dry mouth, nausea, 
somnolence, and sometimes hepatitis. Patients consuming them have 
reported a loss of appetite. The drug is contraindicated in patients 
suffering from glaucoma, liver failure, and renal failure. Hypertensive 
patients must be cautious in using this medication as it has shown an 
increase in blood pressure levels.
Anticonvulsants
Gabapentin and pregabalin are very commonly used anticonvulsants 
in the treatment of neuropathic pain. They work by binding the a-2d 
subunits of the calcium channel and thus reduce the influx of calcium. 
This leads to a decrease in the release of calcium-regulated excitatory 
neurotransmitters like glutamate. Initially, the dose of glutamate is 
300 mg which can be increased up to 1800–3600 mg after a few weeks.
Pregabalin is a second-line drug for treatment and the side effects of 
both the drugs are drowsiness, dry mouth, weight gain, diarrhea, and 
edema [51-53].
Opioids
Opioids have shown moderate effectiveness in the treatment of painful 
DNP. Oxycodone and tramadol are commonly used in the treatment after 
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other drugs have failed to show any effectiveness or have shown adverse 
reactions after prolonged used. Tramadol is a weak inhibitor of serotonin 
and norepinephrine reuptake and acts as a centrally acting opioid agonist. 
A recommended dose of 50 mg in starting dose to 400 mg dose after few 
weeks is advised during the treatment. The common side effects of the 
drug are vomiting, dry mouth, nausea, and constipation [54].
Topical treatments
As capsaicin binds with transient receptor potential vanilloid 1 
receptors which are present on the surface of nociceptive nerve fibers, 
therefore, applying capsaicin-containing topical agents have proved to 
be helpful in treating neuropathic pain.
The patients applying cream themselves must use gloves while applying 
the cream and avoid contact with mucous and eyes. The benefit and role 
of 8% capsaicin are currently under review in the treatment of painful 
DNP [55].
Many patches, creams, and ointments have been used for treatment 
but a comparative and combinational study concluded that gabapentin, 
pregabalin, and duloxetine were equally effective [56].
The drug amitriptyline has proved out to be equally effective as pregabalin, 
but with more side effects in comparison to the latter. A combination 
drug of gabapentin and nortriptyline was proved to be better analgesic 
than a single drug therapy as observed in a crossover trial [57].
We have collected information from published researches and databases 
such as EMBASE, EMB reviews, Medline, and Cochrane central register 
of controlled trials for studying the effective treatment of DNP by the 
systematic review process. A lot of double-blind, randomized trials 
were conducted and drugs such as non-steroidal anti-inflammatory 
drugs, opioid drugs, ion channel blockers, antidepressants, and 
anticonvulsants were used in treating patients. Table 5 states the 
research’s conducted by scientists for treatment for DNP and results 
were collected and evaluated.
The treatment measures for management of the risk factors for diabetes 
are sufficient to prevent any progression of the disease and stabilize it, 
therefore, preventing it from getting worsened.
Anticonvulsant [58-61] trails reported side effects such as dizziness, 
liver derangement, and somnolence. The antidepressant [61,62] therapy 
reflected side effects such as vomiting, headache, pain, nausea and itching. 
No exact adverse reaction other than nausea was published for ion channel 
blockers, [63] whereas opioids [60,64] showed severe adverse reactions 
such as constipation, nausea, vomiting, somnolence, and headache.
Pain management in DNP
Experiencing the neuropathic pain is the most common feature of 
neuropathy. Although there are multiple medications available, still 
the management of the pain is crucial. As recommended by American 
Academy of Neurology in 2011 guidelines, pregabalin 75–150 mg is 
the drug recommended for the treatment of neuropathic pain. Drugs 
such as sodium valproate, gabapentin, amitriptyline, and imipramine 
are also recommended for the management of diabetic pain [66,67]. 
Other topical agents such as transdermal lidocaine and capsaicin are 
also useful for the management of pain.
Animal models
Animal models for research studies on diabetes and DNP
STZ model
In previously mentioned researches, a lot of drugs were tested for 
treating neuropathy before the tests DM, and subsequently, DNP was 
induced. Here are some methods for inducing diabetes and DNP.
An intraperitoneal (i.p) injection of STZ (60 mg/kg dissolved in 0.9% 
NaCl with a pH of 4.0) was given to rats for inducing DM [68,69].
In this research, other seven rats were grouped as control, and therefore, 
they did not receive any amount of drug. Now both the groups were 
tested for blood glucose levels using glucose oxidase reagent strips by 
obtaining blood from the tail tips.
Rats with a glucose level of ≥ 250 mg/dl were included in the study which 
proved to be successfully induced with diabetes. These rats were then used 
for conducting comparative studies as well as to perform activity analysis 
of certain drugs which have proved to cure DNP by histologically examining 
the sciatic nerve or performing motor function tests successfully.
Alloxan model
Alloxan is taken by the liver after administration which acts as a 
protective agent against the ROS. Therefore, it is not vulnerable to 
damage [70,71]. There are different mechanisms reported for alloxan 
which state that it damages the beta cells of the pancreas by oxidation 
of the –SH groups, and especially of glucokinase [72] as well as creates 
a disturbance in the homeostasis of intracellular calcium ions. [73] 
When diabetes is induced using alloxan, then mice are administered 
50–200 mg/kg, whereas rats are given 40–200 mg/kg of alloxan drug 
using i.p or subcutaneous (s.c) injection as the route of administration. 
Table 5: List of conducted trails for treating neuropathy [58‑65]
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These concentrations are 3 times higher than the dose given through 
intravenous (i.v) route [74]. To create long-term diabetes in rabbits, a 
dose of 100 mg/kg of alloxan was given [75].
DISCUSSION
Diabetes causes a major effect on the central nervous system such as 
anorexia, phobias, depression, loss of memory, and reasoning skills 
are also affected by this condition. Diabetes is a prevalent condition 
which is commonly manifested as distal symmetric polyneuropathy 
through many other patterns of nerve injury occurs. As of now, the 
most effective treatment for controlling the neuropathy are monitoring 
glucose controls and pain management. Controlling the glucose causes 
a substantial decrease in the neuropathy for type 1 diabetes though 
the effects are substantially less in cases of type 2 diabetes patients. 
Researches have quoted that using anticonvulsants and antidepressants 
as a therapy for treating pain during management of DNP is fruitful; 
however, the identification of disease-modifying therapies are essential 
when there is a lacuna of disease-modifying therapies for treating DN.
More studies are required to explore therapies for treating DNP 
and finding a suitable cure. In the recent years, diabetologists and 
neurologists are focusing the associated problems from diabetes 
majorly like DNP which is a distressing problem in people suffering from 
diabetes. Medications such as opioids, antidepressants, anticonvulsant, 
ion channel blockers have been used frequently to prevent worsening 
of the disease.
Many reviews have highlighted that people suffering from complications 
of diabetes require multiple therapies, extreme care, and considerations 
to maintaining good health [76]. Therefore, a herbal formulation with 
no side effects is required for curing diabetes-related disorders like 
DNP.
We have deeply reviewed many research papers some of which 
have recommended the incorporation of neurotrophic factors for 
nerve regeneration which is a good source for treating neuropathic 
conditions [77]. Some papers have also mentioned the use of active 
drug molecules, which will undergo changes or alterations in the 
gene expressions to repair the degenerated nerves and cure the DNP 
conditions [78]. A popularly acceptable choice of drug-ethnomedicine 
must be used for treatment of DNP with no notable side effects [79] 
is also urged by the patients as multiple herbal sources have proved 
beneficial in treatment of diabetes [80] and many lifestyle disorders in 
recent years.
Inference
Our interpretation of the review is that in coming years, the diabetic 
population will raise high as compared to the numbers in 2017. As 
DNP is a complication reported in patients, especially when diabetes 
becomes chronic. The nerve damage and pain problems are a major 
concern among the patients and physicians, but drugs available in 
the market are only preventing the progression of the disease and the 
ultimate cure still to be explored.
The oral hypoglycemic agents have proved effective in the treatment of 
Type 2 diabetes [81] therefore it can be taken into consideration that 
using oral formulations for treating DNP ill also prove to be effective 
and with least side effect.
CONCLUSION AND FUTURE PROSPECTIVE
A huge number of side effects are being reported in every trial conducted 
for treating DNP. Moreover, curbing the pain can solve the pain issues in 
neuropathic nerves momentarily, but healing the damaged nerves with 
a potential cure could be an agenda for new researches for treating DNP.
Therefore, developing formulations to exhibit the ultimate cure, relief 
with not much reported adverse reactions is the need currently as 
well as for further benefits. Our future research must be focused 
on ethnomedicine as a potential cure for DNP with reportedly 
lesser adverse reactions. A complete cure to the problem is yet to be 
discovered, although researches are being conducted using natural 
sources and their herbal extracts which might help in reviving the 
damaged nerves and resolving the core cause, thus treating DNP.
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